Docoh
Loading...

NLTX Neoleukin Therapeutics

Employees

Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


On May 13, 2021, Neoleukin Therapeutics, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) and the following proposals were adopted:

1.Election of three Class I Directors, Martin Babler, Erin Lavelle, and Lewis T. “Rusty” Williams, each to serve a three-year term, which will expire at the 2024 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal. The vote tally was as follows:

NomineesShares ForShares WithheldBroker Non-Votes
Martin Babler36,941,36974,2742,338,813
Erin Lavelle36,990,17525,4682,338,813
Lewis T. "Rusty" Williams35,437,4321,578,2112,338,813


2.Ratification of appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021. The vote tally was as follows:

Shares ForShares AgainstShares Abstaining
39,323,76715,31215,377


3.Approval of amendments to the Company's 2014 Equity Incentive Plan. The vote tally was as follows:

Shares ForShares AgainstShares AbstainingBroker Non-Votes
26,110,27110,710,536194,8362,338,813


4.Approval, by non-binding advisory vote, of the compensation paid by the Company to its named officers. The vote tally was as follows:

Shares ForShares AgainstShares AbstainingBroker Non-Votes
35,966,0531,004,73644,8542,338,813